The Proto-Oncogene KRAS and BRAF Profiles and Some Clinical Characteristics in Colorectal Cancer in the Turkish Population

Basit Öğe Kaydı
dc.authoridzemheri, ebru/0000-0003-0247-0332
dc.contributor.authorOzen, Filiz
dc.contributor.authorOzdemir, Semra
dc.contributor.authorZemheri, Ebru
dc.contributor.authorHacimuto, Gizem
dc.contributor.authorSilan, Fatma
dc.contributor.authorOzdemir, Ozturk
dc.date.accessioned2025-01-27T20:46:02Z
dc.date.available2025-01-27T20:46:02Z
dc.date.issued2013
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjectives: The aim of the current study was to investigate the prevalence and predictive significance of the KRAS and BRAF mutations in Turkish patients with colorectal cancer (CRC). Methods: Totally, 53 fresh tumoral tissue specimens were investigated in patients with CRC. All specimens were obtained during routine surgery of patients who were histopathologically diagnosed and genotyped for common KRAS and BRAF point mutations. After DNA extraction, the target mutations were analyzed using the AutoGenomics INFINITI (R) assay, and some samples were confirmed by quantitative real-time polymerase chain reaction fluorescence melting curve analyses. Results: KRAS mutations were found in 26 (49.05%) CRC samples. Twenty-seven samples (50.95%) had wild-type profiles for KRAS codon 12, 13, and 61 in the current cohort. In 17 (65.38%) samples, codon 12; in 7 (26.93%) samples, codon 13; and in 2 (7.69%) samples, codon 61 were found to be mutated, particularly in grade 2 of tumoral tissues. No point mutation was detected in BRAF codon Val600Glu for the studied CRC patients. Conclusions: Our study, based on a representative collection of human CRC tumors, indicates that KRAS gene mutations were detected in 49.05% of the samples, and the most frequent mutation was in the G12D codon. Results also showed that codons 12 and 13 of KRAS are relatively frequently without BRAF mutation in a CRC cohort from the Turkish population.
dc.identifier.doi10.1089/gtmb.2012.0290
dc.identifier.endpage139
dc.identifier.issn1945-0265
dc.identifier.issue2
dc.identifier.pmid23297805
dc.identifier.scopus2-s2.0-84872832597
dc.identifier.scopusqualityQ3
dc.identifier.startpage135
dc.identifier.urihttps://doi.org/10.1089/gtmb.2012.0290
dc.identifier.urihttps://hdl.handle.net/20.500.12428/24791
dc.identifier.volume17
dc.identifier.wosWOS:000313803300010
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMary Ann Liebert Inc
dc.relation.ispartofGenetic Testing and Molecular Biomarkers
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectMutation Status
dc.subjectCarcinoma
dc.subjectAdenocarcinoma
dc.subjectPatient
dc.titleThe Proto-Oncogene KRAS and BRAF Profiles and Some Clinical Characteristics in Colorectal Cancer in the Turkish Population
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu